The main goals of chronic obstructive pulmonary disease (COPD) management include treatment of symptoms and prevention of exacerbations. Current guidelines recommend use of one or more long-acting ...

Please provide your email address to receive an email when new articles are posted on . Minimum pitch in the morning was significantly higher at exacerbation onset and peak vs. baseline. In the ...

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. COPD exacerbations went down by 51% in patients with ...

—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...

Almost 16 million adults have COPD in the United States and about 3 in 4 people with this condition have at least one flare (exacerbation) a year, cites a review. But you don’t have to sit and wait ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

According to a recent study, patients with an exacerbation of chronic obstructive pulmonary disease (COPD) have greater risks of both subsequent exacerbations and mortality. The odds of subsequent ...

Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...

telemedicine Researchers examined the risks for pneumonia and exacerbation of COPD after PPI treatment for GERD. The risk for symptom exacerbation reduced after PPI treatment for patients with GERD ...

Poor quality of sleep was found to have a strong association with symptomatic exacerbations of chronic obstructive pulmonary disease, according to a recent Canadian study presented at the 2016 ...

All dose groups demonstrated good safety and tolerability versus placebo, with similar adverse event (AE) incidence (70% vs. 85%). At the recommended Phase IIb dose (RP2D), the annualized rate of ...